

### AMENDMENTS TO THE CLAIMS

Kindly amend the claims as follows:

1. (Currently amended) A method of treating ~~metastatic~~ tumors in a subject, wherein said tumors result from metastasis, which method comprises:  
administering to a subject afflicted by ~~metastatic~~ said tumors effective amounts of a green porphyrin photosensitizer and an immuno-adjuvant, for inhibiting growth of said ~~metastatic~~ tumors upon irradiation with light comprising a wavelength absorbed by said photosensitizer, wherein said immuno-adjuvant is selected from the group consisting of mycobacterial cell wall skeletons and a derivative of lipid A of a bacterial lipopolysaccharide, and  
irradiating said subject with light comprising a wavelength absorbed by said photosensitizer,  
wherein said subject is treated.

2. (Currently amended) A method of preventing or inhibiting the development of ~~metastatic~~ tumors in a subject, wherein said tumors result from metastasis, which method comprises:  
administering to a subject, at risk for developing ~~metastatic~~ said tumors ~~due to~~ from metastasis of a primary tumor, effective amounts of a green porphyrin photosensitizer and an immuno-adjuvant, to prevent or inhibit the development of ~~metastatic~~ said tumors upon irradiation with light comprising a wavelength absorbed by said photosensitizer, wherein said immuno-adjuvant is selected from the group consisting of mycobacterial cell wall skeletons and a derivative of lipid A of a bacterial lipopolysaccharide, and  
irradiating said subject with light comprising a wavelength absorbed by the photosensitizer,  
whereby the development of ~~metastatic~~ said tumors in said subject is prevented or inhibited.

3. (Previously amended) A method of treating a primary tumor in a subject, which method comprises:

administering to a subject clinically diagnosed with a primary tumor effective amounts of a green porphyrin photosensitizer and an immuno-adjuvant, for inhibiting growth of said primary tumor upon irradiation with light comprising a wavelength absorbed by said photosensitizer, wherein said immuno-adjuvant is selected from the group consisting of mycobacterial cell wall skeletons and a derivative of lipid A of a bacterial lipopolysaccharide, and  
irradiating said subject with light comprising a wavelength absorbed by said photosensitizer,  
whereby said subject is treated.

4. (Original)           The method of claim 2 wherein said subject has previously undergone cancer or tumor therapy.

5. (Previously amended)   The method of claims 1, 2 or 3 wherein said effective amount of a photosensitizer is in the range of 0.05 to 10 milligrams of photosensitizer per kilogram of subject.

6. (Previously amended)   The method of claim 5 wherein said effective amount of a photosensitizer is in the range of 0.05 to 1 milligrams of photosensitizer per kilogram of subject.

7. (Previously amended)   The method of claim 5 wherein said effective amount of a photosensitizer is in the range of 1 to 10 milligrams of photosensitizer per kilogram of subject.

8. (Original)           The method of claims 1 or 3 wherein said photosensitizer is administered intravenously and said immuno-adjuvant is administered by injection into tumors.

9. (Original)           The method of claims 1 or 3 wherein said irradiation is localized to the tumors.

10. (Original)           The method of claim 2 wherein said photosensitizer is administered intravenously or intratumorally.

11. (Previously amended) The method of claims 1, 2 or 3 wherein said photosensitizer is administered to the subject and the subject irradiated before administration of the immuno-adjuvant to the subject.

12. (Original) The method of claims 1, 2 or 3 wherein said immuno-adjuvant is administered systemically.

13. (Previously amended) The method of claims 1, 2 or 3 wherein the photosensitizer is a benzoporphyrin derivative (BPD).

14. (Original) The method of claim 13 wherein the BPD is BPD-MA, EA6, or B3.

15. (Previously amended) The method of claims 1, 2 or 3 further comprising an additional irradiation, before irradiation with light comprising a wavelength absorbed by the photosensitizer, with light of a wavelength which increases penetration of said light absorbed by the photosensitizer into said subject.

16. (Currently amended) The method of claim 1, 2, or 3 wherein said immuno-adjuvant comprises mycobacterial cell wall skeletons and de-3-O-acylated lipid A.

17. (Cancel)

18. (Cancel)

19. (Cancel)

20. (Cancel)

21. (Cancel)